Get the Stockscreener App
23.77
34.98%
6.16
After Hours:
23.57
-0.20
-0.84%
Sarepta Therapeutics Inc stock is traded at $23.77, with a volume of 17.01M.
It is up +34.98% in the last 24 hours and up +25.30% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$17.61
Open:
$19.76
24h Volume:
17.01M
Relative Volume:
5.94
Market Cap:
$2.50B
Revenue:
$2.20B
Net Income/Loss:
$-842.79M
P/E Ratio:
-2.817
EPS:
-8.4382
Net Cash Flow:
$-332.39M
1W Performance:
+38.52%
1M Performance:
+25.30%
6M Performance:
+34.14%
1Y Performance:
-67.71%
1-Day Range:
$19.67
$23.85
1-Week Range:
$16.45
$23.85
52-Week Range:
$10.41
$74.40
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
23.77 | 1.85B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Sarepta Stock Surges 30% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Traders Purchase Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT) - MarketBeat
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Wednesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results - MEXC
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Sarepta Stock Surges 29% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Sarepta (SRPT) Sees Promising Phase 1/2 Results in Neuromuscular Treatment - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpTime to Buy? - MarketBeat
Sarepta sees early success with RNAi drugs from Arrowhead - BioPharma Dive
Sarepta Therapeutics’ experimental siRNA therapies show promising early results - Proactive financial news
Which stocks are gapping on Wednesday? - ChartMill
Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
Sarepta Therapeutics (SRPT) Surges 25% on Promising Trial Data - GuruFocus
SRPT: SRP-1001 and SRP-1003 show potent gene knockdown and safety, advancing toward phase III trials - TradingView
Sarepta (SRPT) Reveals Mixed Results in siRNA Programs for Neuro - GuruFocus
Sarepta Therapeutics shares rise on early promise for rare disease drugs - statnews.com
Sarepta (SRPT) Stock: Rises on Early siRNA Trial Data for Muscular Dystrophy Programs - CoinCentral
Sarepta posts data for muscular dystrophy drugs (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.
Sarepta stock surges 14% on early siRNA trial data By Investing.com - Investing.com Canada
Sarepta shares early trial data for two rare disease therapies - Investing.com
SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases - Stocktwits
Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1 - marketscreener.com
Sarepta shares early clinical data from siRNA treatments for rare diseases - StreetInsider
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta plans to seek full FDA approval of 2 Duchenne treatments - Muscular Dystrophy News
Sarepta Therapeutics: A $2B Business Priced Like It’s Broken (NASDAQ:SRPT) - Seeking Alpha
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares - BioPharma Dive
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada
How FDA Review of Sarepta’s ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - Yahoo Finance
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - MSN
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
SRPT stock up as enrollment begins in DMD gene therapy safety study - MSN
Sarepta to request FDA for traditional approvals for Duchenne drugs - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies - Yahoo Finance
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
MDA 2026: ‘Body of evidence for Elevidys continues to grow’ - Muscular Dystrophy News
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):